Mainz Biomed prices $4M securities offering
Follow-on Offering Details: Mainz Biomed has announced a follow-on offering of 2 million units, aiming to raise approximately $4 million, with each unit priced at $2.00 and consisting of one ordinary share and two types of warrants.
Warrant Information: The Series A and Series B warrants are both immediately exercisable at $2.00 per share, with different expiration conditions; the offering is expected to close around May 21, 2025, pending customary closing conditions.
Trade with 70% Backtested Accuracy
Analyst Views on MYNZ
No data
About MYNZ
About the author
Mainz Biomed Launches eAArly DETECT 2 Clinical Study Covering 2,000 Patients
- Clinical Study Launch: Mainz Biomed initiates the eAArly DETECT 2 clinical study, aiming to evaluate its next-generation colorectal cancer test on approximately 2,000 average-risk patients, which will validate previous leading results and lay the groundwork for future FDA pivotal trials.
- Market Expansion: The ColoAlert® test has received registration from the UK’s MHRA and Swissmedic, marking its debut in the Swiss market and significantly enhancing Mainz Biomed's market share and influence across Europe.
- Strategic Partnerships: The strategic partnership with labor team w ag introduces ColoAlert® to the Swiss market, while collaboration with OncoVanguard8 aims to expand its reach into South America, demonstrating the company's commitment to global market expansion.
- Funding Support: Mainz Biomed's pancreatic cancer project receives public funding from Germany's ISB, covering up to 50% of total project costs, which not only enhances the project's feasibility but also reflects government endorsement of its scientific value.
Mainz Biomed Integrates ColoAlert® Test into DoctorBox Platform in Germany
- Market Expansion: Mainz Biomed's ColoAlert® test has been integrated into DoctorBox, a leading digital health platform in Germany, marking a significant milestone in the company's European growth strategy and expected to greatly enhance access to early cancer detection.
- User Base: With over one million registered users and more than ten million test results, the integration of ColoAlert® will further solidify DoctorBox's leadership in digital preventive healthcare, driving business growth for Mainz Biomed.
- Innovative Collaboration: The partnership with DoctorBox not only lowers barriers to colorectal cancer screening but also enhances user engagement through at-home testing, aligning with modern healthcare service trends.
- Importance of Preventive Care: With approximately 60,000 new colorectal cancer cases diagnosed annually in Germany, the introduction of ColoAlert® provides an effective early detection solution to meet this demand, further advancing the development of personalized preventive healthcare.
Mainz Biomed Partners with DoctorBox to Launch ColoAlert Test in Germany
- Market Expansion: Mainz Biomed's ColoAlert test has been added to DoctorBox's portfolio, marking a significant milestone in the company's European growth strategy and is expected to greatly enhance access to early cancer detection.
- Collaborative Advantage: By partnering with DoctorBox, Mainz Biomed can offer ColoAlert testing in home settings, lowering barriers to colorectal cancer screening and driving innovation in preventive medicine.
- User Base: With over one million registered users and more than ten million test results transmitted, DoctorBox's extensive user base will provide robust support for the promotion of ColoAlert, further enhancing the company's influence in the digital health sector.
- New Standard in Preventive Healthcare: The integration of ColoAlert into DoctorBox's digital platform will make it a cornerstone of next-generation preventive healthcare services, improving user health management experiences significantly.
Mainz Biomed and OncoVanguard8 Partner to Introduce ColoAlert in South America
Collaboration Announcement: Mainz Biomed has signed a Memorandum of Understanding with OncoVanguard8 to introduce its DNA-based colorectal cancer screening test, ColoAlert®, to South America, starting with Peru.
Colorectal Cancer Statistics: Colorectal cancer is highly prevalent and preventable, with around 17,000 new cases diagnosed annually in Peru, Colombia, and Ecuador, emphasizing the need for effective early detection strategies.
Market Strategy: The MOU outlines commercial, legal, and regulatory terms, along with a go-to-market strategy, with plans for a final distribution agreement to be signed soon.
Company Backgrounds: Mainz Biomed specializes in molecular genetic diagnostics for cancer, while OncoVanguard8 focuses on innovative healthcare solutions in Latin America, aiming to enhance cancer prevention and early detection.
Mainz Biomed to Showcase ColoAlert, Its Leading Product, at MEDICA 2025
Company Participation: Mainz Biomed N.V. will participate in MEDICA 2025, a major healthcare trade show in Düsseldorf, Germany, from November 17 to 20, 2025, where it will present its ColoAlert product.
ColoAlert Overview: ColoAlert is a non-invasive, stool-based screening test for early detection of colorectal cancer, combining DNA biomarker analysis with traditional fecal immunochemical testing for improved accuracy.
Regulatory Progress: The test received regulatory approval from Swissmedic in Switzerland on August 13, 2025, and is currently undergoing further clinical validation in the eAArly DETECT 2 study, which is essential for future FDA submission.
Pipeline Updates: At MEDICA 2025, Mainz Biomed will also provide updates on its pipeline, including PancAlert, a new screening test for early-stage pancreatic cancer.
Mainz Biomed to Participate in the 38th Annual GARPS Meeting in Rhineland-Palatinate
Mainz Biomed Participation: Mainz Biomed N.V. will participate in the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS) from November 14-15, 2025, in Bad Kreuznach, Germany, focusing on cancer detection and prevention.
ColoAlert Presentation: The company will showcase its flagship product, ColoAlert®, a non-invasive early-detection test for colorectal cancer, and discuss future diagnostic solutions aimed at enhancing cancer detection.
Networking Opportunities: The conference serves as a platform for Mainz Biomed to strengthen relationships with key opinion leaders in gastroenterology and explore potential collaborations with healthcare professionals.
Forward-Looking Statements: The press release includes forward-looking statements regarding the company's expectations and potential risks, emphasizing the uncertainty surrounding future developments and regulatory approvals.
Mainz Biomed Launches eAArly DETECT 2 Clinical Study Covering 2,000 Patients
- Clinical Study Launch: Mainz Biomed initiates the eAArly DETECT 2 clinical study, aiming to evaluate its next-generation colorectal cancer test on approximately 2,000 average-risk patients, which will validate previous leading results and lay the groundwork for future FDA pivotal trials.
- Market Expansion: The ColoAlert® test has received registration from the UK’s MHRA and Swissmedic, marking its debut in the Swiss market and significantly enhancing Mainz Biomed's market share and influence across Europe.
- Strategic Partnerships: The strategic partnership with labor team w ag introduces ColoAlert® to the Swiss market, while collaboration with OncoVanguard8 aims to expand its reach into South America, demonstrating the company's commitment to global market expansion.
- Funding Support: Mainz Biomed's pancreatic cancer project receives public funding from Germany's ISB, covering up to 50% of total project costs, which not only enhances the project's feasibility but also reflects government endorsement of its scientific value.
Mainz Biomed Integrates ColoAlert® Test into DoctorBox Platform in Germany
- Market Expansion: Mainz Biomed's ColoAlert® test has been integrated into DoctorBox, a leading digital health platform in Germany, marking a significant milestone in the company's European growth strategy and expected to greatly enhance access to early cancer detection.
- User Base: With over one million registered users and more than ten million test results, the integration of ColoAlert® will further solidify DoctorBox's leadership in digital preventive healthcare, driving business growth for Mainz Biomed.
- Innovative Collaboration: The partnership with DoctorBox not only lowers barriers to colorectal cancer screening but also enhances user engagement through at-home testing, aligning with modern healthcare service trends.
- Importance of Preventive Care: With approximately 60,000 new colorectal cancer cases diagnosed annually in Germany, the introduction of ColoAlert® provides an effective early detection solution to meet this demand, further advancing the development of personalized preventive healthcare.
Mainz Biomed Partners with DoctorBox to Launch ColoAlert Test in Germany
- Market Expansion: Mainz Biomed's ColoAlert test has been added to DoctorBox's portfolio, marking a significant milestone in the company's European growth strategy and is expected to greatly enhance access to early cancer detection.
- Collaborative Advantage: By partnering with DoctorBox, Mainz Biomed can offer ColoAlert testing in home settings, lowering barriers to colorectal cancer screening and driving innovation in preventive medicine.
- User Base: With over one million registered users and more than ten million test results transmitted, DoctorBox's extensive user base will provide robust support for the promotion of ColoAlert, further enhancing the company's influence in the digital health sector.
- New Standard in Preventive Healthcare: The integration of ColoAlert into DoctorBox's digital platform will make it a cornerstone of next-generation preventive healthcare services, improving user health management experiences significantly.
Mainz Biomed and OncoVanguard8 Partner to Introduce ColoAlert in South America
Collaboration Announcement: Mainz Biomed has signed a Memorandum of Understanding with OncoVanguard8 to introduce its DNA-based colorectal cancer screening test, ColoAlert®, to South America, starting with Peru.
Colorectal Cancer Statistics: Colorectal cancer is highly prevalent and preventable, with around 17,000 new cases diagnosed annually in Peru, Colombia, and Ecuador, emphasizing the need for effective early detection strategies.
Market Strategy: The MOU outlines commercial, legal, and regulatory terms, along with a go-to-market strategy, with plans for a final distribution agreement to be signed soon.
Company Backgrounds: Mainz Biomed specializes in molecular genetic diagnostics for cancer, while OncoVanguard8 focuses on innovative healthcare solutions in Latin America, aiming to enhance cancer prevention and early detection.
Mainz Biomed to Showcase ColoAlert, Its Leading Product, at MEDICA 2025
Company Participation: Mainz Biomed N.V. will participate in MEDICA 2025, a major healthcare trade show in Düsseldorf, Germany, from November 17 to 20, 2025, where it will present its ColoAlert product.
ColoAlert Overview: ColoAlert is a non-invasive, stool-based screening test for early detection of colorectal cancer, combining DNA biomarker analysis with traditional fecal immunochemical testing for improved accuracy.
Regulatory Progress: The test received regulatory approval from Swissmedic in Switzerland on August 13, 2025, and is currently undergoing further clinical validation in the eAArly DETECT 2 study, which is essential for future FDA submission.
Pipeline Updates: At MEDICA 2025, Mainz Biomed will also provide updates on its pipeline, including PancAlert, a new screening test for early-stage pancreatic cancer.
Mainz Biomed to Participate in the 38th Annual GARPS Meeting in Rhineland-Palatinate
Mainz Biomed Participation: Mainz Biomed N.V. will participate in the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS) from November 14-15, 2025, in Bad Kreuznach, Germany, focusing on cancer detection and prevention.
ColoAlert Presentation: The company will showcase its flagship product, ColoAlert®, a non-invasive early-detection test for colorectal cancer, and discuss future diagnostic solutions aimed at enhancing cancer detection.
Networking Opportunities: The conference serves as a platform for Mainz Biomed to strengthen relationships with key opinion leaders in gastroenterology and explore potential collaborations with healthcare professionals.
Forward-Looking Statements: The press release includes forward-looking statements regarding the company's expectations and potential risks, emphasizing the uncertainty surrounding future developments and regulatory approvals.
